AzTrials
AzTrials

Intra Cerebral HemorrhagePhase 1/2BBBDNCT01830894

Feasibility Study of New MRI Protocol in Assessing Early Blood Brain Barrier Disruption (BBBD)in Related to Delay Brain Edema

A Phase 1/2 study testing MRI in people with Intra Cerebral Hemorrhage, run by Sheba Medical Center at 1 site in Israel.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

MRI research Group in the Advanced Technology Center of the Sheba Medical Center has developed an innovative methodology based on leakage (extravasation) contrast agent that allows to map the entire brain with high resolution and high sensitivity to check and describe disorders BBB (blood brain barrier). Read more about this study

Who is it for?
Ages 18 to 80 years
Conditions the study is for
Intra Cerebral Hemorrhage
What is being tested?
MRI
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
30 participants
Where
1 siteIsrael
Study dates
Apr 2013to Jun 2014
Phase
Phase 1/2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age between 18-80 years.
  • patient is able to sign the informed consent form.
  • Spontaneous brain hemorrhage ICH in the last12 hours ( pre- admission,or sub- dural bleeding (whether acute or chronic ).

Who cannot join

  • The patient meets a contraindication to undergo MRI.
  • The patient is too unstable to undergo MRI
  • The patient is a candidate for surgery within 24 hours.

Trial locations and contacts

1 site in 1 country.

Israel1 site
  • Sheba medical center, Tel Hashomer

    Ramat Gan, 52621

Other trials in Israel

About this study

Official title: Evaluation and Correlation Between the Disruption in Blood-brain-barrier and the Development of Secondary Brain Edema Associated With Brain Damage by Using MRI in Patients With Various Types of Intra-cranial Bleeding

MRI research Group in the Advanced Technology Center of the Sheba Medical Center has developed an innovative methodology based on leakage (extravasation) contrast agent that allows to map the entire brain with high resolution and high sensitivity to check and describe disorders BBB (blood brain barrier).

The aim of the current study is to evaluate the feasibility of the BBB disruption detection method to predict delayed peri - hemorrhage edema.

Read the detailed description

Research's Protocol:

Evaluation and Correlation between the disruption in blood-brain-barrier and the development of secondary brain edema associated with brain damage by using MRI in patients with various types of intra-cranial bleeding .

Research team:

Main (Primary researcher):

Sagi Harnof MD , Neurosurgery department, Sheba medical center, Tel Hashomer

Secondary researchers:

Prof. David Tanne (M.D), Neurology department .

Dr. Yael Mardor (PhD), Advanced technology department.

Dr. Oded Goren (M.D), Neurosurgery department.

Dr. Masswadeh Ahmad (M.D), Neurosurgery Department.

Background :

Spontaneous brain hemorrhage is one of the most difficult issues in strokes concept regarding underlying pathology, reasons and treatment.

Etiology:

  • General prevalence of about approximately 10-15% in all strokes.
  • Mortality and morbidity associated with it are the most severe with mortality rates of up to 50-60%.

There are various pathologies thought to be responsible for bleeding, most commonly known to be :

hypertension, Angiopathies, amyloidotic or vascular problems and space occupying lesions.

Treatment process that takes place is very limited and most patients are treated only conservatively.

Cytotoxic brain edema that develops around the bleeding results usually from local cell damage and local pressure. It usually increases in the first days after bleeding and is considered to be one of the main causes of deterioration after cerebral hemorrhage .

Sub-dural cerebral hemorrhage is a common disease due to traumatic injury, often with serious consequences.

Regarding the natural history of subdural bleeding, not only It's believed to be difficult predicting the bleeding's course, but the risk to induce cerebral edema and later on to develop into chronic sub Dural bleeding is unpredictable as well .

Nevertheless chronic sub-dural bleeding is one of the most common cases seen in neurosurgery practice, But worthy to notify that only little is known about the pathogenesis of the disease, appearance of symptoms , preferable time for drainage and its complications .

Although hasn't been contributing much in clinical evaluation of stoke, MRI has a growing importance in the field of stroke lately .

In a previous neuro-imaging research that included patients after ischemic stroke it was shown that with an innovative methodology based on leakage extravasation) contrast agent in MRI which allows to map the entire brain with high resolution, we can easily evaluate the sensitivity disorder in BBB .

In 27% of patients who showed no anomalies at BBB in normal MRI, calculated maps with late leakage showed significant volumes of BBB opening ischemic areas.

MRI research Group in the Advanced Technology Center of the Sheba Medical Center has developed an innovative methodology based on leakage (extravasation) contrast agent that allows to map the entire brain with high resolution and high sensitivity to check and describe disorders BBB.

Data Acquisition:

MRI will be performed using the General Electric (GE) T3.0/1.5 with a standard head coil of 8 channels.

MRI scans will include high-resolution spin-echo T1-weighted MRI , acquired before and at several time points after injection (1, 12, 20, 23, 30, 70 minutes after injection).

T1-MRI may be done with Echo Time (TE) / Repetition Time (TR) = 22/240 ms, field of view 26 x 19.5 inch, 5/0.5 mm slice thickness and 512x512 - pixels.

To notify : T1-MRI data is acquired simultaneously with any conventional imaging protocol accepted at Sheba Medical center by routine practice. (Sheba's routine).

Type of study:

A prospective feasibility study performed on a group of patients with cerebral hemorrhage.

The purpose of the study:

  1. Assess the ability to characterize quantitatively the BBB disruption around cerebral hemorrhage.
  2. Find a correlation between the degree of BBBD immediately after bleeding and cerebral edema 3-5 days after bleeding.
  3. Search for clinical correlation between the degree of BBBD immediately after the bleeding and the clinical course that follows it later on.

Methods:

This is a prospective study aimed to test the feasibility of using BBBD protocol in MRI in order to predict the development of edema and clinical deterioration.

Course of the experiment:

Once the -on call- neurosurgery resident is notified about a patient with spontaneous ICH he would contact any of the researchers to begin the screening process for participation in the study. Patients who had undergone intracranial hemorrhage (ICH) that was discovered in the past twelve hours will undergo a screening process performed by any of the researchers in order to determine whether or not they meet the inclusion criteria. Such patients may arrive from the emergency room, intensive care unit or any of the other wards in the hospital.

  1. An initial Baseline MRI is to be done:
  2. for spontaneous ICH bleeding - within 6-24 hours from the bleeding.
  3. for chronic sub dural bleeding - at the time of diagnosis .
  4. for acute sub-dural bleeding - within 6-24 hours from the bleeding.

It should be emphasized that the purpose of the MRI is to assess the extent of BBBD and is intended for research purposes only. This MRI protocol does not allow complete diagnostic assessment. .

Whether the patient needs an accompanying doctor while in MRI or not, is solely determined by a researcher, depending on the patient's clinical situation.

  1. Clinical follow-up : neurological status, registration of National Institutes of Health Stroke Scale (NIHSS questionnaire). a- for spontaneous bleeding - Daily monitoring \& registering National Institutes of Health Stroke Scale (NIHSS) for five consequent days. Additional clinical follow-up will be performed two weeks later. b- for chronic or acute sub-dural bleeding follow up visit after 14 days.
  2. second MRI which serves as review :
  3. for spontaneous intra-cranial bleeding: on the 3rd -5th day after bleeding.
  4. For chronic sub Dural bleeding : within two weeks.
  5. For acute sub Dural bleeding: within two weeks.
  6. Two months later, third MRI will be reviewed for all types of bleeding.
  7. Result - Analysis of the outcomes as follows: Search correlation between BBBD and clinical status. Search BBBD correlation with hematoma growth. Search correlation between BBBD and the development of cerebral edema. Search correlation between BBBD and growth process of Chronic Subdural Hematoma (CSDH) Search correlation between BBBD and the drainage of CSDH. Search correlation between BBBD while Acute Subdural Hematoma (ASDH) is converted to CSDH.
Being tested
MRI
Medical subject headings
Cerebral Hemorrhage

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • MRIDevice

    Also called BBB disruption detection algorithm using Gad enhanced MR

    3 MRI on different times during the study for each arm.

Study groups in NCT01830894
Study groupRoleWhat they receive
spontaneous ICH bleedingExperimentalAn initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - on the 3rd -5th day after bleeding
Receives: Device: MRI
chronic sub dural bleedingExperimentalAn initial Baseline MRI is to be done at the time of diagnosis. second MRI which serves as review -within two weeks.
Receives: Device: MRI
acute sub-dural bleedingExperimentalAn initial Baseline MRI is to be done within 6-24 hours from the bleeding. second MRI which serves as review - within two weeks.
Receives: Device: MRI

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. delayed peri - hemorrhage edema as a relation to early BBB disruption

    early BBB disruption will be calculated from Gad enhanced magnetic resonance (MR) and a correlation to late volume of edema as calculated using 3D methods will be assessed

    Measured: 1 week

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Apr 2013 (estimated)
  2. Study startApr 2013
  3. Primary completionApr 2014 (estimated)
  4. Study completionJun 2014 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1/2
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
30 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01830894
Sponsor's protocol ID
SHEBA-12-9889-SH-CTIL
Acronym
BBBD
Status last verified
Mar 2013
First submitted
10 Apr 2013
Last updated
12 Apr 2013
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 1/2 study testing MRI in people with Intra Cerebral Hemorrhage, run by Sheba Medical Center at 1 site in Israel.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 12 Apr 2013. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Sagi Harnof, MD (+972-52-6666291, Sagi.HarNof@sheba.health.gov.il), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

delayed peri - hemorrhage edema as a relation to early BBB disruption (time frame: 1 week). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Apr 2013.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in